RT Journal Article
SR Electronic
T1 First-in-Human Imaging with <sup>89</sup>Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1858
OP 1864
DO 10.2967/jnumed.116.176206
VO 57
IS 12
A1 Pandit-Taskar, Neeta
A1 O’Donoghue, Joseph A.
A1 Ruan, Shutian
A1 Lyashchenko, Serge K.
A1 Carrasquillo, Jorge A.
A1 Heller, Glenn
A1 Martinez, Danny F.
A1 Cheal, Sarah M.
A1 Lewis, Jason S.
A1 Fleisher, Martin
A1 Keppler, Jennifer S.
A1 Reiter, Robert E.
A1 Wu, Anna M.
A1 Weber, Wolfgang A.
A1 Scher, Howard I.
A1 Larson, Steven M.
A1 Morris, Michael J.
YR 2016
UL http://jnm.snmjournals.org/content/57/12/1858.abstract
AB We conducted a phase I dose-escalation study with 89Zr-desferrioxamine-IAB2M (89Zr-IAB2M), an anti–prostate-specific membrane antigen minibody, in patients with metastatic prostate cancer. Methods: Patients received 185 MBq (5 mCi) of 89Zr-IAB2M and Df-IAB2M at total mass doses of 10 (n = 6), 20 (n = 6), and 50 mg (n = 6). Whole-body and serum clearance, normal-organ and lesion uptake, and radiation absorbed dose were estimated, and the effect of mass escalation was analyzed. Results: Eighteen patients were injected and scanned without side effects. Whole-body clearance was monoexponential, with a median biologic half-life of 215 h, whereas serum clearance showed biexponential kinetics, with a median biologic half-life of 3.7 (12.3%/L) and 33.8 h (17.9%/L). The radiation absorbed dose estimates were 1.67, 1.36, and 0.32 mGy/MBq to liver, kidney, and marrow, respectively, with an effective dose of 0.41 mSv/MBq (1.5 rem/mCi). Both skeletal and nodal lesions were detected with 89Zr-IAB2M, most visualized by 48-h imaging. Conclusion: 89Zr-IAB2M is safe and demonstrates favorable biodistribution and kinetics for targeting metastatic prostate cancer. Imaging with 10 mg of minibody mass provides optimal biodistribution, and imaging at 48 h after injection provides good lesion visualization. Assessment of lesion targeting is being studied in detail in an expansion cohort.